Keyword: NSCLC

Roche’s Alecensa topped Pfizer’s Xalkori in previously untreated ALK+ lung cancer, setting it up for a potential showdown with Pfizer and Novartis.

With a new green light in Europe in lung cancer, Novartis just took another step in expanding the market for its targeted Tafinlar-plus-Mekinist combination therapy.

With a full FDA approval granted Friday, AstraZeneca’s lung cancer med Tagrisso is in position to become the standard of care for certain patients with the deadly disease, a company exec predicts.

Merck’s Keytruda is making waves in the U.S. market as a first-line treatment for non-small cell lung cancer. But it won’t be doing so in England—at least not yet.